Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection

Oncotarget

Volumn 6, Issue 22, 2015, Pages 19217-19227

  Jin, Junfei ^a   Zhu, Pengpeng ^a   Liao, Yan ^b   Li, Jun ^a   Liao, Weijia ^a   He, Songqing ^a  

^a GUILIN MEDICAL UNIVERSITY   (China)

^b Ctr for Dis Contr/Prev of Guilin   (China)

Author keywords

Hepatocellular carcinoma; Oncology; Prognosis; Therapy; Treatment

Indexed keywords

ASPARTATE AMINOTRANSFERASE;

ADULT; AGE; ARTICLE; ASPARTATE AMINOTRANSFERASE TO LYMPHOCYTE RATIO INDEX; CANCER PROGNOSIS; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER RESECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PREDICTIVE VALUE; PREOPERATIVE PERIOD; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE; TUMOR THROMBUS; TUMOR VOLUME; BLOOD; CARCINOMA, HEPATOCELLULAR; ENZYMOLOGY; LIVER NEOPLASMS; LYMPHOCYTE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RISK FACTOR;

ASPARTATE AMINOTRANSFERASES; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84938901698     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4265     Document Type: Article

References (55)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142:1264-1273.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74-108.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
4. Danese E, Montagnana M, Minicozzi AM, Bonafini S, Ruzzenente O, Gelati M, et al. The role of resistin in colorectal cancer. Clin Chim Acta. 2012; 413:760-764.
5. Zhang GM, Xia YJ, Guo XX, Zhu BL, Zhang GM, Ma XB, et al. Reference intervals for total bilirubin, ALT, AST and creatinine in healthy Chinese elderly. Med Sci Monit. 2014; 20:1778-1782.
6. van Beek JH, de Moor MH, de Geus EJ, Lubke GH, Vink JM, Willemsen G, et al. The genetic architecture of liver enzyme levels: GGT, ALT and AST. Behav Genet. 2013; 43:329-339.
7. Lee TH, Kim WR, Benson JT, Therneau TM, Melton LJ 3rd. Serum aminotransferase activity and mortality risk in a United States community. Hepatology. 2008; 47:880-887.
8. Witjes CD, IJzermans JN, van der Eijk AA, Hansen BE, Verhoef C, de Man RA. Quantitative HBV DNA and AST are strong predictors for survival after HCC detection in chronic HBV patients. Neth J Med. 2011; 69:508-513.
9. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140:883-899.
10. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420:860-867.
11. Tarao K, Miyakawa K, Miyagi Y, Ohkawa S, Morinaga S, Oshige K, et al. Severe inflammation in the background liver cirrhosis correlates with the development of poorly differentiated HCC in HCV-associated liver cirrhosis. Intern Med. 2012; 51:2495-2501.
12. Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer. 2012; 48:1977-1987.
13. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454:436-444.
14. Ko E, Jung G. Positive association of long telomeres with the invasive capacity of hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2014; 447:358-363.
15. Mossanen JC, Tacke F. Role of lymphocytes in liver cancer. Oncoimmunology. 2013; 2:e26468. [PubMed: 24498546]
16. Shibolet O, Alper R, Zlotogarov L, Thalenfeld B, Engelhardt D, Rabbani E, et al. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Int J Cancer. 2003; 106:236-243.
17. Guo CL, Yang HC, Yang XH, Cheng W, Dong TX, Zhu WJ, et al. Associations between infiltrating lymphocyte subsets and hepatocellular carcinoma. Asian Pac J Cancer Prev. 2012; 13:5909-5913.
18. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology. 2002; 122:366-375.
19. Yamashita Y, Shirabe K, Toshima T, Tsuijita E, Takeishi K, Harimoto N, et al. Risk factors for recurrence after curative resection of hepatitis C-related hepatocellular carcinoma in patients without postoperative interferon therapy. Hepatol Res. 2013; 43:1313-1320.
20. Lin YJ, Lee MH, Yang HI, Jen CL, You SL, Wang LY, et al. Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. PLoS One. 2013; 8:e61448.
21. Mera JR, Dickson B, Feldman M. Influence of gender on the ratio of serum aspartate aminotransferase (AST) to alanine aminotransferase (ALT) in patients with and without hyperbilirubinemia. Dig Dis Sci. 2008; 53:799-802.
22. Hann HW, Wan S, Lai Y, Hann RS, Myers RE, Patel F, et al. AST to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic HBV infection. J Gastroenterol Hepatol. 2015; 30:131-138.
23. Shen SL, Fu SJ, Chen B, Kuang M, Li SQ, Hua YP, et al. Preoperative Aspartate Aminotransferase to Platelet Ratio is an Independent Prognostic Factor for Hepatitis B-Induced Hepatocellular Carcinoma After Hepatic Resection. Ann Surg Oncol. 2014; 21:3802-3809.
24. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011; 53:726-736.
25. Borsoi Viana MS, Takei K, Collarile Yamaguti DC, Guz B, Strauss E. Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C. Ann Hepatol. 2009; 8:26-31.
26. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132:2557-1576. ]
27. Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010; 29:1093-1102.
28. Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut. 2012; 61:427-438.
29. Schneider C, Teufel A, Yevsa T, Staib F, Hohmeyer A, Walenda G, et al. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut. 2012; 61:1733-1743.
30. Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, et al. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 2003; 63:4095-4100.
31. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S , Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011; 71:1263-1271.
32. Zimmermann HW, Tacke F. Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm Allergy Drug Targets. 2011; 10:509-536.
33. Tian Z, Chen Y, Gao B. Natural killer cells in liver disease. Hepatology. 2013; 57(4):1654-1662. [PubMed: 23111952]
34. Subleski JJ, Wiltrout RH, Weiss JM. Application of tissue-specific NK and NKT cell activity for tumor immunotherapy. J Autoimmun. 2009; 33:275-281.
35. Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol. 2008; 129:428-437.
36. Stojanovic A, Cerwenka A. Natural killer cells and solid tumors. J Innate Immun. 2011; 3:355-364.
37. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011; 479:547-551.
38. Ormandy LA, Farber A, Cantz T, Petrykowska S, Wedemeyer H, Horning M, et al. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol. 2006; 12:3275-3282.
39. Fu J, Zhang Z, Zhou L, Qi Z, Xing S, Lv J, et al. Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology. 2013; 58:139-149.
40. Witkowski M, Spangenberg HC, Neumann-Haefelin C, Büttner N, Breous E, Kersting N, et al. Lack of ex vivo peripheral and intrahepatic alpha-fetoprotein-specific CD4+ responses in hepatocellular carcinoma. Int J Cancer. 2011; 129:2171-2182.
41. Baitsch L, Baumgaertner P, Devêvre E, Raghav SK, Legat A, Barba L, et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest. 2011; 121:2350-2360.
42. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev. 2011; 239:27-44.
43. Chan KM, Chou HS, Wu TJ, Lee CF, Yu MC, Lee WC. Characterization of hepatocellular carcinoma recurrence after liver transplantation: perioperative prognostic factors, patterns, and outcome. Asian J Surg. 2011; 34:128-134.
44. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009; 29:502-510.
45. Yeh CT, Huang YH, Liang KH, Chang ML, Hsu CW, Chen YC, et al. Segregation of signaling proteins as prognostic predictors for local recurrence and distant metastasis in hepatocellular carcinoma. Int J Oncol. 2014; 44:491-504.
46. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol. 2006; 12:7561-7567.
47. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010; 51:1274-1283.
48. Lau WY, Sangro B, Chen PJ, Cheng SQ, Chow P, Lee RC, et al. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology. 2013; 84:311-318.
49. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006; 243:229-235.
50. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011; 331:1559-1564.
51. Chen YL, Ko CJ, Chien SY, Chen LS, Chen ML, Chi CW, et al. Tumor size as a prognostic factor in resected small hepatocellular carcinoma: a controversy revisited. J Gastroenterol Hepatol. 2011; 26:851-857.
52. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008; 359:1995-2004.
53. Li Y, Li DJ, Chen J, Liu W, Li JW, Jiang P, Zhao X, Guo F, Li XW, Wang SG, et al. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma. Asian Pac J Cancer Prev. 2015;16:3451-3455.
54. Chen YL, Chen CH, Hu RH, Ho MC, Jeng YM, et al. Elevated Preoperative Serum CA19-9 Levels in Patients with Hepatocellular Carcinoma Is Associated with Poor Prognosis after Resection. Scientific World Journal. 2013; 2013:380797.
55. Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB: the official journal of the International Hepato Pancreato Biliary Association. 2005; 7:26-34.